

History of the Daiichi Sankyo Group


Challenging to continue contributing to patients throughout a history of over 100 years

Daiichi Sankyo continues to challenge the creation of innovative pharmaceuticals by leveraging the strengths of Science & Technology (S&T) that have been passed down over a long period of 100 years. Moving forward, we will continue to create innovative pharmaceuticals sourced from S&T, addressing the unmet medical needs of each era, and “contributing to the enrichment of quality of life around the world” through the realization of our 2030 Vision.

History as a pharma innovator (major products over the years)

- 1899**
Launched Taka-Diastase®, a digestive enzyme agent
- 1902**
Adrenalin, an adrenal cortex hormone agent
- 1915**
Began domestic manufacturing of Salvarsan, a therapeutic drug for syphilis
- 1922**
Began manufacturing of Bosmin®, a vasoconstriction/hemostasis and asthma medicine
- 1951**
Manufactured Chloromycetin®, the first antibiotic produced in Japan
- 1965**
Transamin®, a hemostatic and anti-inflammatory agent
- 1985**
Tarivid®, a broad-spectrum oral antimicrobial agent
- 1986**
Loxonin®, an anti-inflammatory analgesic
- 1989**
Mevalotin®, hypercholesterolemia treatment
- 1993**
Cravit®, a broad-spectrum oral antimicrobial agent
- 2002**
Olmesartan (Olmotec. in Japan and Europe, Benicar. in the United States), an antihypertensive agent

Our 5-year business plan



Breakthrough proprietary products that address “the unmet medical needs” of each era.

Infectious diseases (tuberculosis and pneumonia)

Lifestyle-related diseases

Cancer, dementia, and emerging and re-emerging infectious diseases

- 2009**
Efient®, an antiplatelet agent
- 2010**
Inavir®, anti-influenza treatment
- 2011**
Lixiana®, an anticoagulant

- 2019**
Tarlige®, pain treatment
- 2020**
Enhertu®, an anti-cancer agent (HER2 directed antibody drug conjugate)
- 2023**
DAICHIRONA®, for intramuscular injection vaccine against COVID-19